Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: A single center experience

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 8, 2013, Pages 1190-1196

  Omer, Aazim K ^a   Ziakas, Panayiotis D ^b   Anagnostou, Theodora ^c   Coughlin, Erin ^c   Kourkoumpetis, Themistoklis ^d   McAfee, Steven L ^c   Dey, Bimalangshu R ^c   Attar, Eyal ^c   Chen, Yi Bin ^c   Spitzer, Thomas R ^c   Mylonakis, Eleftherios ^b   Ballen, Karen K ^c  

^a NORTH SHORE MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; CD34+ cell; Invasive fungal disease

Indexed keywords

CD34 ANTIGEN; FLUCONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INDUCTION CHEMOTHERAPY; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34(+) CELL; INVASIVE FUNGAL DISEASE;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84880406360     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.05.018     Document Type: Article

References (61)

1. Jantunen E., Salonen J., Juvonen E., et al. Invasive fungal infections in autologous stem cell transplant recipients: A nation-wide study of 1188 transplanted patients. Eur J Haematol 2004, 73:174-178.
2. Jantunen E., Nihtinen A., Volin L., et al. Candidaemia in allogeneic stem cell transplant recipients: Low risk without fluconazole prophylaxis. Bone Marrow Transplant 2004, 34:891-895.
3. Kriengkauykiat J., Ito J.I., Dadwal S.S. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol 2011, 3:175-191.
4. Martino R., Subira M., Rovira M., et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients. Br J Haematol 2002, 116:475-482.
5. Hagen E.A., Stern H., Porter D., et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003, 36:9-15.
6. Morgan J., Wannemuehler K.A., Marr K.A., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol 2005, 43(Suppl 1):S49-S58.
7. Bow E.J. Invasive fungal infection in haematopoietic stem cell transplant recipients: Epidemiology from the transplant physician's viewpoint. Mycopathologia 2009, 168:283-297.
8. Hung C.Y., Kao K.C., Wang P.N., et al. Invasive fungal infection among hematopoietic stem cell transplantation patients with mechanical ventilation in the intensive care unit. BMC Infect Dis 2012, 12:44.
9. Camps I.R. Risk factors for invasive fungal infections in hematopoietic stem cell transplantation. Int J Antimicrob Agents 2008, 32(Suppl 2):S119-S123.
10. Safdar A., Rodriguez G.H., Mihu C.N., et al. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: Spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 2010, 45:339-347.
11. Kontoyiannis D.P., Marr K.A., Park B.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50:1091-1100.
12. Ziakas P.D., Kourbeti I.S., Voulgarelis M., Mylonakis E. Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: A meta-analysis of randomized controlled trials. Clin Ther 2010, 32:2316-2336.
13. Jantunen E., Ruutu P., Niskanen L., et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997, 19:801-808.
14. Fukuda T., Boeckh M., Carter R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003, 102:827-833.
15. Garcia-Vidal C., Upton A., Kirby K.A., Marr K.A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008, 47:1041-1050.
16. Neofytos D., Horn D., Anaissie E., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
17. Ramos E.R., Jiang Y., Hachem R., et al. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: The role of novel antimold azoles. Oncologist 2011, 16:1049-1060.
18. Brunstein C.G., Weisdorf D.J., DeFor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006, 108:2874-2880.
19. Blennow O., Remberger M., Klingspor L., et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant 2010, 45:1710-1718.
20. Barnes P.D., Marr K.A. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007, 139:519-531.
21. Li L., Wang J., Zhang W., et al. Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: A single center study of 190 recipients. Scand J Infect Dis 2012, 44:100-107.
22. Zhang P., Jiang E.L., Yang D.L., et al. Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: A single-institution experience. Transpl Infect Dis 2010, 12:316-321.
23. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
24. Pauw B.D., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
25. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
26. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: A joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005, 106:1495-1500.
27. Labopin M, Latouche A, Suciu S, etal. Definitions and evaluation of endpoints following stem cells transplantation: Recommendation from the European Group for Blood and Marrow Transplantation (EBMT). Available from: Accessed 2009. http://portal.ebmt.org/sites/clint2/clint/Documents/Statistical%20Endpoints_CLINT%20Project_final%20version.pdf.
28. Bull K., Spiegelhalter D.J. Survival analysis in observational studies. Stat Med 1997, 16:1041-1074.
29. Labbé A.C., Su S.H., Laverdière M., et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host-disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007, 13:1192-1200.
30. Mikulska M., Raiola A.M., Bruno B., et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009, 44:361-370.
31. Wald A., Leisenring W., van Burick J.A., Bowden R.A. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. JInfect Dis 1997, 175:1459-1466.
32. Ben-Ami R., Lewis R.E., Kontoyiannis D.P. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 2009, 22:376-384.
33. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol Blood Marrow Transplant 2002, 8:512-520.
34. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001, 98:3221-3227.
35. + peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003, 17:869-875.
36. + cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005, 19:822-828.
37. Kałwak K., Porwolik J., Mielcarek M., et al. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after invivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 2010, 16:1388-1401.
38. + cell dose and overall survival in patients undergoing invivo T-cell depleted, but not T-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 2011, 4:149-156.
39. + cell dose. Blood 2009, 114:2606-2616.
40. Bittencourt H., Rocha V., Chevret S., et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002, 99:2726-2733.
41. Brown J., Boussiotis V.A. Umbilical cord blood transplantation: Basic biology and clinical challenges to immune reconstitution. Clin Immunol 2008, 127:286-297.
42. Jacobson C.A., Turki A.T., McDonough S.M., et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: Comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:565-574.
43. Suzuya H., Watanabe T., Nakagawa R., et al. Factors associated with granulocyte colony-stimulating factor induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005, 89:229-235.
44. + cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). JClin Apheresis 2006, 21:169-175.
45. Burroughs L., Mielcarek M., Little M.T., et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005, 106:4002-4008.
46. Flomenberg N., Devine S.M., DiPersio J.F., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
47. Hess D.A., Bonde J., Craft T.C., et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007, 13:398-411.
48. Cashen A.F., Lazarus H.M., Devine S.M. Mobilizing stem cells from normal donors: Is it possible to improve upon G-CSF?. Bone Marrow Transplant 2007, 39:577-588.
49. Devine S.M., Vij R., Rettig M., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
50. Pusic I., DiPersio J.F. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 2010, 17:319-326.
51. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomeswith HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
52. Sun Y.Q., Xu L.P., Liu D.H., et al. The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without invitro T-cell depletion. Clin Microbiol Infect 2012, 18:997-1003.
53. Cohen J., Gandhi M., Naik P., et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005, 129:229-239.
54. Kim D.H., Baek J.H., Kim J.G., et al. Clinical significance of platelet count at day+60 after allogeneic peripheral blood stem cell transplantation. JKorean Med Sci 2006, 21:46-51.
55. Kim D.H., Sohn S.K., Jeon S.B., et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant 2006, 37:101-108.
56. Cornely O.A., Bohme A., Reichert D., et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. JAntimicrob Chemother 2008, 61:939-946.
57. El-Cheikh J., Castagna L., Wang L., et al. Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 2010, 51:1705-1710.
58. Maziarz R.T., McLeod A., Chen M., et al. Outcomes of allogeneic HSCT for patients with hematologic malignancies (AML, ALL, MDS, CML) with and without pre-existing fungal infections: A CIBMTR study. Biol Blood Marrrow Transplant 2013, 19:S124-S125.
59. Marty F.M., Lowry C.M., Cutler C.S., et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:552-559.
60. Said A., Garnick J.J., Dieterle N., et al. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006, 26:289-295.
61. Huang X., Chen H., Han M., et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2012, 18:1509-1516.